Lymphokine-activated killer cell and natural killer cell activities in patients with systemic sclerosis

Arthritis Rheum. 1992 Jun;35(6):694-9. doi: 10.1002/art.1780350615.

Abstract

Objective: To determine the ability of T lymphocytes and natural killer (NK) cells from patients with systemic sclerosis (SSc) to respond to cytokines and to generate immune effector cells.

Methods: The numbers and percentages of peripheral blood T and NK cells were examined by 2-color flow cytometry, and NK and lymphokine-activated killer (LAK) cell function were measured in 4-hour 51Cr-release assays, in 34 patients with SSc. The patients were categorized into 3 subgroups: 10 had diffuse cutaneous disease of less than or equal to 3 years disease duration, 11 had diffuse cutaneous SSc of greater than 3 years duration, and 13 had limited cutaneous disease.

Results: Baseline and activated NK and T cell numbers and NK activity were normal in SSc patients. However, mean LAK activity was significantly depressed in all SSc subgroups.

Conclusion: Decreased LAK cell function, despite normal numbers of circulating T and NK cells, indicates that SSc patients have poor ability to produce effector cells in response to interleukin-2.

MeSH terms

  • Adult
  • Antigens, CD / analysis
  • Antigens, Differentiation / analysis
  • Antigens, Differentiation, T-Lymphocyte / analysis
  • CD56 Antigen
  • CD8 Antigens / analysis
  • Humans
  • Interleukin-2 / pharmacology
  • Killer Cells, Lymphokine-Activated / drug effects
  • Killer Cells, Lymphokine-Activated / immunology*
  • Killer Cells, Lymphokine-Activated / metabolism
  • Killer Cells, Natural / immunology*
  • Leukocyte Count
  • Middle Aged
  • Receptors, Fc / analysis
  • Receptors, IgG
  • Scleroderma, Systemic / blood
  • Scleroderma, Systemic / immunology*
  • T-Lymphocyte Subsets / immunology

Substances

  • Antigens, CD
  • Antigens, Differentiation
  • Antigens, Differentiation, T-Lymphocyte
  • CD56 Antigen
  • CD8 Antigens
  • Interleukin-2
  • Receptors, Fc
  • Receptors, IgG